Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 01, 2026
Veeva Systems (VEEV) Surges +10.11% on S&P 500 Inclusion

Veeva Systems (VEEV) Surges +10.11% on S&P 500 Inclusion

Key Takeaways

  • VEEV shares surged 10.11% to $171.75 in today's trading session from the previous close of $155.97.
  • Primary catalyst: Announcement that VEEV will join the S&P 500 index effective May 7, replacing Coterra Energy (CTRA).
  • Pre-market trading saw gains exceeding 10%, extending into regular hours with strong momentum.
  • Broader market context: S&P 500 up over 1%, software sector showing sympathy gains.
  • Traders watching index fund inflows, upcoming Q1 fiscal 2026 earnings on May 28, and AI integration updates. I'm keeping an eye on these developments closely.

Today's Rally in Veeva Systems

Veeva Systems Inc. (VEEV), a leading provider of cloud-based software solutions for the global life sciences industry, saw its shares rally sharply today. The stock climbed 10.11% to $171.75 from the prior session's close of $155.97. From what I see, this move reflects market enthusiasm following the late announcement of VEEV's inclusion in the S&P 500 index.

The S&P 500 Inclusion Driving the Gains

The key driver behind today's price rally was S&P Dow Jones Indices' disclosure that VEEV will replace Coterra Energy (CTRA) in the S&P 500 effective prior to the open of trading on May 7. This addition typically triggers significant buying from index-tracking funds and ETFs, which must adjust holdings to match the benchmark. VEEV shares jumped more than 10% in pre-market trading, signaling strong anticipation of passive inflows estimated in the hundreds of millions.

Noted investor Michael Burry highlighted the stock as "still cheap" despite the surge, adding to positive sentiment amid VEEV's year-to-date decline of around 30% versus the S&P 500's gains. One thing that stands out to me is how this positions VEEV for broader investor attention.

Market Context and Trading Details

Trading volume for VEEV has been elevated compared to its average daily volume of approximately 2 million shares, reflecting heightened investor interest. The stock opened at $156.44, quickly pushing past recent highs toward $171.75 intraday. This outperformed the broader market, with the S&P 500 advancing over 1%, and aligned with strength in software and healthcare IT peers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Technically, the rally broke above the 50-day moving average and prior resistance levels near $160, suggesting potential for further upside on sustained buying. The move diverged positively from energy stocks like CTRA, which saw modest gains.

Trending AI Robots

One resource I turn to in volatile sessions like today's VEEV surge is Tickeron’s Trending AI Robots page, which showcases the platform’s top-performing AI-driven trading bots under current market conditions. Tickeron offers hundreds of AI bots covering thousands of tickers across various strategies, timeframes, and performance metrics, including pattern recognition, momentum, and mean reversion approaches. The curated trending section highlights only the strongest live performers, helping me identify tools that adapt dynamically to such moves. I find it valuable for enhancing my trading edge with data-backed automation.

What's Next for VEEV

Investors will monitor passive fund rebalancing ahead of the May 7 index inclusion. VEEV is scheduled to report fiscal 2026 first-quarter results on May 28, with focus on subscription revenue growth, AI product adoption, and guidance amid life sciences sector dynamics. In my view, analyst consensus remains positive on long-term prospects, though competitive pressures in cloud software persist. Key risks include macroeconomic slowdowns affecting biopharma spending and execution on expansion initiatives.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.

Related Ticker: VEEV

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


VEEV's RSI Oscillator leaves overbought zone

The 10-day RSI Indicator for VEEV moved out of overbought territory on August 21, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 instances where the indicator moved out of the overbought zone. In of the 33 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VEEV broke above its upper Bollinger Band on August 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on VEEV as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for VEEV just turned positive on July 29, 2026. Looking at past instances where VEEV's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 189 cases where VEEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.513) is normal, around the industry mean (7.638). P/E Ratio (43.954) is within average values for comparable stocks, (46.808). Projected Growth (PEG Ratio) (1.111) is also within normal values, averaging (1.726). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (6.460).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 2.95B. The market cap for tickers in the group ranges from 708 to 40.27B. VEEV holds the highest valuation in this group at 40.27B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was 1%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 25%. TEM experienced the highest price growth at 40%, while ONMD experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 4%. For the same stocks of the Industry, the average monthly volume growth was -51% and the average quarterly volume growth was -90%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 76
Price Growth Rating: 52
SMR Rating: 86
Profit Risk Rating: 98
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
VEEV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of industry-specific, cloud-based software solutions for the life sciences industry

Industry ServicestotheHealthIndustry

Profile
Details
Industry
Packaged Software
Address
4280 Hacienda Drive
Phone
+1 925 452-6500
Employees
7172
Web
https://www.veeva.com
Interact to see
Advertisement
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.